Health

Health and lifestyle features.

UNITAID investments to bring innovative HIV diagnostic technologies to world's poorest

UNITAID today announced the largest investment yet in “point-of-care” and decentralized HIV diagnostic products to bring life-saving technologies out of the drug development pipeline and into remote communities most affected by the epidemic. 

Press Conference: UNITAID, CHAI-UNICEF and MSF to Bring Cutting-Edge HIV Diagnostic Technologies to World's Poorest

A new set of investments by global health initiative UNITAID will revolutionize the HIV/AIDS response in low-income countries by bringing new and advanced HIV diagnostics to patients in the most remote communities.

Kenta Biotech registriert ersten Patienten für den „First-in-human“-Versuch mit dem vielversprechenden mono-klonalen Antikörper KBSA301

Kenta Biotech hat heute einen wichtigen Schritt für eine effektivere Behandlung von Spitalinfektionen angekündigt: Der erste Patient wurde für die klinische Phase I/II-Studie mit KBSA301 registriert. KBSA301 ist ein rein humaner Antikörper zur Behandlung schwerer Lungenentzündungen, die durch Staphylococcus aureus-Bakterien (S. aureus) verursacht werden.

Kenta Biotech includes first patient in its first-in-human trial of promising monoclonal antibody KBSA301

Kenta Biotech today announced an important step towards a more efficient treatment of hospital infections: The first patient was enrolled in the phase I/II clinical trial with KBSA301, a fully human antibody for the treatment of severe pneumonia caused by Staphylococcus aureus (S. aureus).

UNITAID approves US$ 30 million for innovative project to roll out ground-breaking tuberculoses test at reduced cost

The executive board of UNITAID today approved funding of US$ 30 million to scale up access to a new diagnostic test for tuberculosis, Xpert MTB/RIF, and reduce the cost of its use.

Kenta Biotech vollzieht mit Umzug in den Bio-Technopark Zürich-Schlieren wichtigen strategischen Schritt

Kenta Biotech verlegt ihren Firmensitz von Bern in den Bio-Technopark in Zürich-Schlieren, dem Silicon Valley der Schweizer Biotechnologie.

Kenta Biotech makes strategic move by relocating to Bio-Technopark in Zurich-Schlieren

Kenta Biotech announced today that it is relocating from Bern to Bio-Technopark in Zurich-Schlieren, the Silicon Valley of Swiss Biotechnology.

Kenta Biotech erhält Status der EU für einen humanen monoklonalen Antikörper gegen schwere pneumonien

Kenta Biotech hat heute bekannt gegeben, dass die Europäische Kommission ihrem Produkt KBSA301 den Status eines Medikaments für seltene Krankheiten (Orphan Drug) erteilt hat.

Kenta Biotech obtains EU Orphan Drug Status for antibody against pneumonia

Kenta Biotech announced today that the European Commission has granted 'Orphan Drug' status to Kenta Biotech’s product KBSA301 for the treatment of severe pneumonia caused by Staphylococcus aureus (S. aureus).

Bladder cancer – we know more, but still not enough…

Action on Bladder Cancer (ABC) releases findings from a new National survey* exposing how little the general public knows about bladder cancer.

Pages

Subscribe to RSS - Health